170 related articles for article (PubMed ID: 28633975)
1. Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion.
Torgeman A; Mador N; Dorozko M; Lifshitz A; Eschar N; White MD; Wolf DG; Epstein E
Biologicals; 2017 Jul; 48():24-27. PubMed ID: 28633975
[TBL] [Abstract][Full Text] [Related]
2. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.
Burnouf T; Terpstra F; Habib G; Seddik S
Biologicals; 2007 Oct; 35(4):329-34. PubMed ID: 17363271
[TBL] [Abstract][Full Text] [Related]
3. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
4. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products.
Reid KG; Cuthbertson B; Jones AD; McIntosh RV
Vox Sang; 1988; 55(2):75-80. PubMed ID: 3142151
[TBL] [Abstract][Full Text] [Related]
5. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.
Johnston A; Uren E; Johnstone D; Wu J
Biologicals; 2003 Sep; 31(3):213-21. PubMed ID: 12935811
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of West-Nile virus during peptic cleavage of horse plasma IgG.
Lazar A; Epstein E; Lustig S; Barnea A; Silberstein L; Reuveny S
Biologicals; 2002 Jun; 30(2):163-5. PubMed ID: 12127318
[TBL] [Abstract][Full Text] [Related]
7. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
[TBL] [Abstract][Full Text] [Related]
8. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
Remington KM; Trejo SR; Buczynski G; Li H; Osheroff WP; Brown JP; Renfrow H; Reynolds R; Pifat DY
Vox Sang; 2004 Jul; 87(1):10-8. PubMed ID: 15260817
[TBL] [Abstract][Full Text] [Related]
10. Physiochemical properties of enveloped viruses and arginine dictate inactivation.
Meingast CL; Joshi PU; Turpeinen DG; Xu X; Holstein M; Feroz H; Ranjan S; Ghose S; Li ZJ; Heldt CL
Biotechnol J; 2021 Jul; 16(7):e2000342. PubMed ID: 33877739
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution.
Dichtelmüller H; Rudnick D; Kloft M
Biologicals; 2002 Jun; 30(2):135-42. PubMed ID: 12127315
[TBL] [Abstract][Full Text] [Related]
12. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
13. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
14. Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.
Gugerell A; Sorgenfrey D; Laggner M; Raimann J; Peterbauer A; Bormann D; Suessner S; Gabriel C; Moser B; Ostler T; Mildner M; Ankersmit HJ
Blood Transfus; 2020 Jan; 18(1):30-39. PubMed ID: 30865581
[TBL] [Abstract][Full Text] [Related]
15. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
16. Virus inactivation at moderately low pH varies with virus and buffer properties.
Joshi PU; Meingast CL; Xu X; Holstein M; Feroz H; Ranjan S; Ghose S; Li ZJ; Heldt CL
Biotechnol J; 2022 Feb; 17(2):e2100320. PubMed ID: 34874097
[TBL] [Abstract][Full Text] [Related]
17. Clearance of porcine circovirus and porcine parvovirus from porcine-derived pepsin by low pH inactivation and cation exchange chromatography.
Yang B; Wang H; Kaleas K; Butler M; Franklin J; Bill A; Baylis SA; Chen Q; Blümel J
Biotechnol Prog; 2020 Jul; 36(4):e2968. PubMed ID: 31989781
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
19. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
20. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
